A Phase II Study of Lenalidomide and Low-Dose Dexamethasone in Combination with Dalteparin in Previously Untreated Multiple Myeloma.

Trial Profile

A Phase II Study of Lenalidomide and Low-Dose Dexamethasone in Combination with Dalteparin in Previously Untreated Multiple Myeloma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Dalteparin sodium; Dexamethasone
  • Indications Embolism and thrombosis; Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Mar 2017 Planned End Date changed from 1 Jan 2017 to 31 Dec 2017.
    • 02 Mar 2017 Status changed from active, no longer recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top